Parabilis Medicines closed a $305 million Series F to accelerate development of its corkscrew-shaped peptide therapeutics, funding late-stage advancement of its lead oncology candidate. The financing was oversubscribed and positions the company to scale preclinical and clinical programs while retaining private ownership as it eyes larger trials and potential IPO options. Parabilis’ technology focuses on cell-penetrant peptides designed to reach intracellular targets often labeled “undruggable.” Company executives framed the round as essential to move their lead compound into late-stage testing and to expand the platform across tumor types. Investors in the round signaled confidence in the modality’s potential to overcome barriers faced by larger biologics. The raise underscores investor demand for novel modalities that can access intracellular protein surfaces. Parabilis’ funds will support IND-enabling work, larger clinical cohorts, and commercial-prep activities ahead of pivotal trials.